1. Home
  2. COLL vs IRMD Comparison

COLL vs IRMD Comparison

Compare COLL & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$45.38

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo iRadimed Corporation

IRMD

iRadimed Corporation

HOLD

Current Price

$99.90

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COLL
IRMD
Founded
2002
1992
Country
United States
United States
Employees
N/A
160
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
COLL
IRMD
Price
$45.38
$99.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
1
Target Price
$51.17
$72.00
AVG Volume (30 Days)
512.5K
77.5K
Earning Date
02-26-2026
02-12-2026
Dividend Yield
N/A
0.68%
EPS Growth
N/A
13.00
EPS
1.63
1.65
Revenue
$757,067,000.00
$80,511,268.00
Revenue This Year
$26.17
$15.17
Revenue Next Year
$3.65
$10.15
P/E Ratio
$28.19
$60.84
Revenue Growth
26.34
12.91
52 Week Low
$23.23
$47.48
52 Week High
$50.79
$104.93

Technical Indicators

Market Signals
Indicator
COLL
IRMD
Relative Strength Index (RSI) 44.14 53.70
Support Level $44.43 $99.57
Resistance Level $48.29 $104.93
Average True Range (ATR) 2.15 2.69
MACD -0.25 -0.35
Stochastic Oscillator 31.27 39.32

Price Performance

Historical Comparison
COLL
IRMD

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Share on Social Networks: